Abstract:Colorectal cancer (CRC) is the third leading cause of cancer-associated mortality worldwide. Ginsenoside Rh1 (Rh1) is a traditional medicine monomer with antitumor activity; however, the effects of Rh1 in CRC remain to be determined. In the present study, SW620 cells were treated with different concentrations of Rh1. Cell Counting Kit-8, wound healing and Transwell assays were performed to measure cell viability and proliferation, migration and invasion, respectively. Subsequently, the mRNA expression levels of matrix metallopeptidase (MMP)1, MMP3 and tissue inhibitor of metalloproteinases 3 (TIMP3) were detected by reverse transcription-quantitative PCR analysis. In addition, the protein expression levels of MMP1, MMP3, TIMP3, and total or phosphorylated (p-)ERK1/2, P38, JNK were detected by western blotting. Furthermore, tumor growth was examined in a nude mouse xenograft model. The results of the present study indicated that Rh1 was not toxic to CRC cells at various concentrations (0, 50 or 100 µM) and treatment durations (24 or 48 h). However, cell proliferation was suppressed by Rh1 in a dose-dependent manner. Rh1 (100 µM) significantly inhibited cell migration and invasion in vitro. Additionally, Rh1 suppressed the mRNA and protein expression of MMP1 and MMP3, and promoted TIMP3 expression. Rh1 decreased the ratios of p-P38/P38, p-ERK1/2/ERK1-2 and p-JNK/JNK in vitro and in vivo, which suggested that Rh1 inactivated the mitogen-activated protein kinase (MAPK) signaling pathway. Notably, Rh1 markedly decreased tumor volume and weight in vivo. In conclusion, the present study demonstrated that Rh1 inhibited the proliferation, migration and invasion of CRC cells in vitro and tumor growth in vivo. This inhibition was at least partially due to the inhibition of MMP1 and MMP3 expression, the increase in TIMP3 expression level and the MAPK signaling pathway inactivation. Therefore, Rh1 may effectively inhibit the development of CRC as an anticancer drug, and may have a supporting effect during CRC treatment.

Ginsenoside Rh2 Suppresses Growth of Uterine Leiomyoma in Vitro and in Vivo and May Regulate ERα/c-Src/p38 MAPK Activity

Ginsenoside Rh2 inhibits breast cancer cell growth via<?A3B2 ACK?>ERβ-TNFα pathway

Octyl Ester of Ginsenoside Rh2 Induces Apoptosis and G1 Cell Cycle Arrest in Human HepG2 Cells by Activating the Extrinsic Apoptotic Pathway and Modulating the Akt/p38 MAPK Signaling Pathway.

Ginsenoside Rd from Panax Notoginseng is Cytotoxic Towards HeLa Cancer Cells and Induces Apoptosis

Ginsenoside Rh2 Induces HeLa Apoptosis through Upregulating Endoplasmic Reticulum Stress-Related and Downstream Apoptotic Gene Expression.

Ginsenoside Rh2 Inhibits Proliferation and Induces Apoptosis in Human Leukemia Cells Via TNF-α Signaling Pathway.

Anti-Warburg Mechanism of Ginsenoside F2 in Human Cervical Cancer Cells via Activation of miR193a-5p and Inhibition of β-Catenin/c-Myc/Hexokinase 2 Signaling Axis

Ginsenoside Rh2 impedes proliferation and migration and induces apoptosis by regulating NF‐κB, MAPK, and PI3K/Akt/mTOR signaling pathways in osteosarcoma cells

Ginsenoside Rh1 regulates gastric cancer cell biological behaviours and transplanted tumour growth in nude mice via the TGF-beta/Smad pathway

Ginsenoside Rh2 Inhibits HeLa Cell Energy Metabolism and Induces Apoptosis by Upregulating Voltage‑dependent Anion Channel 1.

Antitumor and Immunomodulatory Effects of Ginsenoside Rh2 and Its Octyl Ester Derivative in H22 Tumor-Bearing Mice

Ginsenoside Rh2 suppresses colon cancer growth by targeting the miR-150-3p/SRCIN1/Wnt axis

Ginsenoside Rh2 stimulates the production of mitochondrial reactive oxygen species and induces apoptosis of cervical cancer cells by inhibiting mitochondrial electron transfer chain complex

Ginsenoside Rh1 Inhibits Colorectal Cancer Cell Migration and Invasion in Vitro and Tumor Growth in Vivo

Ginsenoside Rg1 Exerts Estrogen-Like Activities Via Ligand-Independent Activation of ERα Pathway

Korean Red Ginseng attenuates Di-(2-ethylhexyl) phthalate-induced inflammatory response in endometrial cancer cells and an endometriosis mouse model

Identification of 20(<i>S</i>)-Ginsenoside Rh2 as a Potential EGFR Tyrosine Kinase Inhibitor

Ginsenoside Rb1 inhibits proliferation and promotes apoptosis by regulating HMGB1 in uterine fibroid cells.

Ginsenoside Rh2 Inhibits Prostate Cancer Cell Growth Through Suppression of Microrna‐4295 That Activates CDKN1A

Ginsenoside Rh2 Induces Apoptosis and Paraptosis-Like Cell Death in Colorectal Cancer Cells Through Activation of P53.

Mitogen-activated protein kinase (MAPK) pathway mediates the oestrogen-like activities of ginsenoside Rg1 in human breast cancer (MCF-7) cells.